Since all the OCAv3-detected RET fusions and NTRK fusions were subsequently confirmed with the ThyroSPEC Panel, future primary molecular stratifications of progressive RAI-resistant metastatic and ATA high recurrence risk thyroid cancers with structural incomplete response in the Alberta Healthcare regions will be performed with the ThyroSPEC Panel. Here, RET is linked to thyroid cancer.